
CATX Stock Forecast & Price Target
CATX Analyst Ratings
Bulls say
Perspective Therapeutics is a radiopharmaceutical company with a lead program targeting somatostatin receptor for neuroendocrine tumors, which is a ~$39B addressable market. The company also has a newly disclosed program targeting CCK2R with up to $6B in additional TAM. With a differentiated vertically integrated approach and upcoming data catalysts, we see Perspective Therapeutics as a leader in the next-gen radiopharmaceutical space and expect the stock to appreciate as data emerges across key pipeline programs.
Bears say
Perspective Therapeutics is facing regulatory discussions and uncertainty regarding their pipeline drugs and upcoming data releases. Their current projected peak sales and market share may not be achievable, especially in a highly competitive market. Additionally, their current valuation is based on lofty revenue and sales projections, which may be overly optimistic and not realistic in the long term. Furthermore, the company's recent financial data shows a net loss of $9 million and a decrease in cash and cash equivalents by $93 million, signaling potential financial struggles in the future.
This aggregate rating is based on analysts' research of Perspective Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
CATX Analyst Forecast & Price Prediction
Start investing in CATX
Order type
Buy in
Order amount
Est. shares
0 shares